Premium
Evolution of Systemic Therapy for Hepatocellular Carcinoma
Author(s) -
Finn Richard S.,
Zhu Andrew X.
Publication year - 2021
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.31306
Subject(s) - hepatocellular carcinoma , medicine , systemic therapy , oncology , clinical trial , selection (genetic algorithm) , drug development , intensive care medicine , cancer , drug , pharmacology , computer science , artificial intelligence , breast cancer
Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development. That has changed in the past several years, with the results from a number of hallmark phase 3 studies in advanced HCC. In HCC, immune‐oncology approaches have garnered much attention; there is still a need to better understand criteria for patient selection and to optimize combination strategies to maximize the potential of these approaches. The next generation of studies will aim at translating our increased understanding of tumor biology into clinical trial design.